Dr. Davis on IMvigor130 Trial in Metastatic Urothelial Cancer

Nancy B. Davis, MD, group leader, Urology Oncology, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, discusses the results of the phase III IMvigor130 trial in metastatic urothelial cancer.

Although the overall survival data were not statistically significant in patients who received first-line atezolizumab (Tecentriq) in combination with chemotherapy versus chemotherapy plus placebo, a trend toward improvement was reported with the addition of atezolizumab to chemotherapy.

Median progression-free survival at 11.8 months was 8.2 months with atezolizumab/chemotherapy versus 6.3 months with chemotherapy/placebo (HR, 0.82; 95% CI, 0.70-0.96; P = .007).

According to these results, Davis believes that immunotherapy will play an important role in this space. Novel combinations of immunotherapy plus FGFR inhibitors like erdafitinib (Balversa) could be introduced, she adds. Additionally, neoadjuvant immunotherapy data are anticipated for platinum-ineligible patients, concludes Davis.